Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA‐ARIA) ‐ EIP on AHA Twinning Reference Site (GARD research demonstration project)

Abstract

The overarching goals of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) are to enable European citizens to lead healthy, active and independent lives whilst ageing. The EIP on AHA includes 74 Reference Sites. The aim of this study was to transfer innovation from an app developed by the MACVIA-France EIP on AHA reference site (Allergy Diary) to other reference sites. The phenotypic characteristics of rhinitis and asthma multimorbidity in adults and the elderly will be compared using validated information and communication technology (ICT) tools (i.e. the Allergy Diary and CARAT: Control of Allergic Rhinitis and Asthma Test) in 22 Reference Sites or regions across Europe. This will improve the understanding, assessment of burden, diagnosis and management of rhinitis in the elderly by comparison with an adult population. Specific objectives will be: (i) to assess the percentage of adults and elderly who are able to use the Allergy Diary, (ii) to study the phenotypic characteristics and treatment over a 1-year period of rhinitis and asthma multimorbidity at baseline (cross-sectional study) and (iii) to follow-up using visual analogue scale (VAS). This part of the study may provide some insight into the differences between the elderly and adults in terms of response to treatment and practice. Finally (iv) work productivity will be examined in adults.

The Allergic Rhinitis and its Impact on Asthma (ARIA) score of allergic rhinitis using mobile technology correlates with quality of life: The MASK study

“…EQ‐5D is a MAFEIP (Monitoring and assessment framework for the EIP on AHA) tool, and the present study is in line with the EIP on AHA. This is another important finding as the Transfer of Innovation of the Allergy Diary is an EIP on AHA scaling up project …”

Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence

“…18,19 It uses a treatment scroll list including all medications customized for each country, as well as VASs to assess rhinitis control and work productivity. MASK is deployed in 23 countries and 17 languages, 55 For all of these recommendations, the level of evidence was low 2,3 or very low. Oral corticosteroid as a short course and an add-on treatment T5…”

Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology

“…A Transfer of Innovation (Twinning) project has been funded by the European Innovation Partnership on Active and Healthy Ageing by using MASK in 25 reference sites or regions across Europe, Argentina, Australia, Brazil, Colombia, and Mexico. 64 The number of countries is increasing, and MASK should be rapidly operative in the United States, China, India (in English only), and Japan. This will improve the understanding, assessment of burden, diagnosis, and management of rhinitis in old age by comparison with an adult population.…”

“…Finally, the transfer of innovation of ARIA has been carried out to the reference sites of the European Innovation Partnership on Active and Healthy Ageing. 64 This CM2 guiding coalition is already in place in the European Forum for Research and Education in Allergy and Airways Diseases (http://www.euforea.eu). 67 Develop a vision and strategy.…”